Abstract
Introduction: Lisocabtagene Maraleucel (Liso-cel) is a second-generation Chimeric Antigen Receptor T-cell (CAR-T) therapy product targeting CD19. It is currently being evaluated for B-cell lymphomas with pivotal trials conducted in Aggressive B-cell Lymphomas Areas covered: To prepare this article reviewing preclinical and clinical data studying Liso-cel, we performed a Pubmed search using the terms ‘JCAR017’ and ‘Lisocabtagene maraleucel’. Pre-clinical work done with Liso-cel demonstrate the synergistic activity of CD4 + T-cells and CD8+ central memory T-cells (TCM) at a predefined ratio of 1:1. The trial, TRANSCEND NHL001 in aggressive B-cell lymphoma, confirms robust antitumor activity while demonstrating manageable toxicity profile. Expert Opinion: There are inherent differences amongst the three CD19 directed CAR-T products. This could explain the differences in efficacy and safety profiles of the products. In the absence of randomized data, it would be scientifically unsound to prioritize one product over another. Nevertheless, when aiming to balance efficacy and safety, current prospective data indicate that Liso-cel is well positioned with impressive response rates.
| Original language | English |
|---|---|
| Pages (from-to) | 1151-1156 |
| Number of pages | 6 |
| Journal | Expert Opinion on Biological Therapy |
| Volume | 21 |
| Issue number | 9 |
| DOIs | |
| State | Published - 2021 |
Bibliographical note
Publisher Copyright:© 2021 Informa UK Limited, trading as Taylor & Francis Group.
Funding
G Hildebrandt reports receiving advisory board fees from Pfizer, Kite Pharma, Incyte, Jazz Pharmaceuticals, Morphosys, Alexion Pharmaceuticals, Karyopharm Therapeutics and Seattle Genetics; receiving research funding from Takeda, Jazz Pharmaceuticals, Pharmacyclics, Incyte and Astra Zeneca; receiving funding towards travel & accommodation from the Falk foundation, Pfizer, Kite Pharma, Incyte, Jazz Pharmaceuticals, Astellas Pharma and Takeda; and having equity interest in Axim biotechnologies, Novartis, Insys Therapeutics, Abbvie, GW Pharmaceuticals, Cardinal Health, Clovis Oncology, Cellectis, CVS Health, Celgene, Bluebird Bio, Bristol-Myers Squibb, crispr therapeutics, Endocyte, IDEXX Laboratories, Immunomedics, Johnson & Johnson, Kite Pharma, Pfizer, Proctor & Gamble, Vertex, Bayer, Scotts-Miracle, Charlottes Webb CWBHF, AImmune Therapeutics, Medical PPTYS, Caretrust Reit Inc CTRE, ANGI Homeservices. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
| Funders | Funder number |
|---|---|
| Falk Foundation | |
| Pfizer | |
| Takeda Pharmaceuticals U.S.A. | |
| Jazz Pharmaceuticals | |
| CVS Health Foundation |
Keywords
- Acute lymphoblastic leukemia
- B-cell
- CAR-T
- CD19
- JCAR017
- Lisocabtagene Maraleucel
- Lymphoma
- T-cell subset
- aggressive b-cell lymphoma
- chimeric antigen receptor T-cell therapy
- large B-cell lymphoma
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry